New NEJM Analyses Contrast Pradaxa, Eliquis and Xarelto In VTE
Executive Summary
Pradaxa proves effective for prevention of recurrent VTE in two trials – RE-MEDY and RE-SONATE – with one comparing the drug to warfarin and the other to placebo. But Pradaxa also has a significantly higher rate of myocardial infarction compared to warfarin that is difficult to explain. Meanwhile, Eliquis’ safety profile suggests potential for change in treatment paradigm.